Author: Kathryn Ardizzone

Joint comments on NIH patent license to Molecular Targeting Technologies, Inc. over Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors (and the NIH’s Response)

Posted on by Kathryn Ardizzone

(UPDATE: The NIH provided a response to our comments on August 28, 2019) On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063 on the “Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics… Continue Reading →

Joint comments on proposed NIH patent license to Tailored Therapeutics for the development and commercialization of cell therapies for cancer (and the NIH’s Response)

Posted on by Kathryn Ardizzone

(UPDATE: The NIH provided a response to our comments on July 11, 2019) On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063, on the “Prospective Grant of an Exclusive Patent License: Development… Continue Reading →